Roche's Tarceva and AstraZeneca's own Iressa are the current standard of care in first line treatments of patients with locally advanced or metastatic EGFR+ lung cancer, but Tagrisso looks set to ...

and Roche’s Tarceva (erlotinib). Over time. most targeted cancer drugs have their efficacy limited by the development of resistance mutations. As exon 20 mutated NSCLC is pretty rare the patient ...

The global cancer therapeutics and biotherapeutics market size was evaluated at USD 194.15 billion in 2024 and is expected to attain USD 440.59 billion by 2034, growing at a CAGR of 8.54% from 2025 to ...